Note 16 - Collaborative Agreements (Details Textual) - Tuspetinib Licensing Agreement [Member] $ in Millions |
Nov. 04, 2021
USD ($)
shares
|
|---|---|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
| License Fee, Total | $ 12.5 |
| Payments for License Fee | 5.0 |
| Stock Issued During Period, Value, Licensing Fee | $ 7.5 |
| Stock Issued During Period, Shares, Licensing Fees (in shares) | shares | 7,190 |
| Clinical Development and Global Regulatory Milestone, First Indication | $ 64.5 |
| Clinical Development and Global Regulatory Milestone, Second Indication | 34.0 |
| Clinical Development and Global Regulatory Milestone, Third Indication | 29.0 |
| Global Sales Milestone | $ 280.0 |
| X | ||||||||||
- Definition Represents the target clinical development and global regulatory milestones for the first indication. No definition available.
|
| X | ||||||||||
- Definition Represents the target clinical development and global regulatory milestones for the second indication. No definition available.
|
| X | ||||||||||
- Definition Represents the target clinical development and global regulatory milestones for the third indication. No definition available.
|
| X | ||||||||||
- Definition Represents the target global sales milestone. No definition available.
|
| X | ||||||||||
- Definition Represents total license fee. No definition available.
|
| X | ||||||||||
- Definition Represents cash outflow for license fee. No definition available.
|
| X | ||||||||||
- Definition Shares of stock issued for licensing fees. No definition available.
|
| X | ||||||||||
- Definition Value of stock issued as a result of licensing fee. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|